Karen Wilson, C.P.A. has served as one of the LAVA Therapeutics supervisory directors since March 2021. She currently serves on the board of directors of Elicio Therapeutics, Inc. (formerly Angion Biomedica) and Connect Biopharma. She previously served on the board of directors of Vaxart, Inc. Ms. Wilson served as senior vice president of finance at Jazz Pharmaceuticals plc until September 2020 after serving as vice president of finance and principal accounting officer. Prior to joining Jazz Pharmaceuticals in February 2011, Ms. Wilson served as vice president of finance and principal accounting officer at PDL BioPharma, Inc. She also previously served as a principal at the consulting firm of Wilson Crisler LLC, chief financial officer of ViroLogic, Inc., chief financial officer and vice president of operations for Novare Surgical Systems, Inc., and as a consultant and auditor for Deloitte & Touche LLP. Ms. Wilson is a certified public accountant and received a bachelor of science degree in business from the University of California, Berkeley.